Mink to Report Q3 Financial Results and Clinical Updates on November 11

Mink announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on November 11, 2026. The company will host a conference call and webcast that morning to review the financial results and provide updates on its lead therapy, agenT-797, and strategic initiatives. These updates will include progress on the randomized Phase 2 evaluation of agenT-797 in acute lung injury and new findings from the Society for Immunotherapy of Cancer 2026 Annual Meeting.

Mink is a clinical-stage biopharmaceutical company specializing in allogeneic invariant natural killer T cell therapies. The company's progress reflects efforts to validate its therapies clinically and overcome barriers to patient access, including contributions to an ARPA-H-funded collaboration on deployable cell therapeutics.